7-year update on a Phase II trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for CLL VJHemOnc – Video Journal of Hematology & HemOnc 4:44 5 months ago 289 Далее Скачать
Six-year update from CLL14: fixed-duration venetoclax + obinutuzumab for previously untreated CLL VJHemOnc – Video Journal of Hematology & HemOnc 1:43 1 year ago 297 Далее Скачать
Outcomes in high-risk CLL patients following fixed-duration treatment with ibrutinib plus venetoclax VJHemOnc – Video Journal of Hematology & HemOnc 2:43 1 year ago 621 Далее Скачать
Four-year follow-up from a Phase II study of obinutuzumab, ibrutinib, and venetoclax in CLL VJHemOnc – Video Journal of Hematology & HemOnc 2:43 2 years ago 317 Далее Скачать
The future of fixed-duration therapy in CLL VJHemOnc – Video Journal of Hematology & HemOnc 1:56 2 years ago 127 Далее Скачать
CAPTIVATE: fixed-duration ibrutinib plus venetoclax in patients with CLL/SLL VJHemOnc – Video Journal of Hematology & HemOnc 1:23 3 years ago 175 Далее Скачать
Update on fixed-duration cohort of CAPTIVATE trial for CLL/SLL VJHemOnc – Video Journal of Hematology & HemOnc 2:27 3 years ago 216 Далее Скачать
3-year follow-up of obinutuzumab, ibrutinib and venetoclax for CLL VJHemOnc – Video Journal of Hematology & HemOnc 6:34 4 years ago 1 213 Далее Скачать
7-year follow-up of RESONATE-2 trial for CLL/SLL VJHemOnc – Video Journal of Hematology & HemOnc 2:05 3 years ago 235 Далее Скачать
CLL2-GiVe trial: ibrutinib, venetoclax and obinutuzumab in patients with TP53-mutated CLL VJHemOnc – Video Journal of Hematology & HemOnc 1:36 1 year ago 197 Далее Скачать
Dr. Smith on the Rationale Behind the Fixed Duration Trial for Ibrutinib/Venetoclax in CLL OncLive 1:31 5 years ago 314 Далее Скачать
Obinutuzumab plus ibrutinib and venetoclax treatment continues to yield high response rates in CLL VJHemOnc – Video Journal of Hematology & HemOnc 1:36 3 years ago 97 Далее Скачать
Fixed-duration ibrutinib and venetoclax for first-line CLL ecancer 7:36 3 years ago 123 Далее Скачать
Achieving undetectable MRD with ibrutinib plus venetoclax for CLL VJHemOnc – Video Journal of Hematology & HemOnc 1:53 3 years ago 219 Далее Скачать
Christine Ryan, MD, Discusses Phase II Results of Acalabrutinib, Venetoclax, Obinutuzumab in CLL Blood Cancers Today 4:26 1 year ago 83 Далее Скачать
MAJIC: Venetoclax with acalabrutinib or obinutuzumab in CLL VJHemOnc – Video Journal of Hematology & HemOnc 1:09 2 years ago 690 Далее Скачать
Fixed-duration treatment strategies for frontline and relapsed CLL VJHemOnc – Video Journal of Hematology & HemOnc 0:56 1 year ago 172 Далее Скачать
Overcoming resistance in CLL VJHemOnc – Video Journal of Hematology & HemOnc 2:01 3 years ago 198 Далее Скачать
GLOW: primary analysis of ibrutinib plus venetoclax versus obinutuzumab plus chlorambucil in CLL VJHemOnc – Video Journal of Hematology & HemOnc 3:34 3 years ago 206 Далее Скачать
Time-limited venetoclax-obinutuzumab +/- ibrutnib surpasses CIT in frontline CLL ecancer 4:29 2 years ago 91 Далее Скачать
